{
    "clinical_study": {
        "@rank": "139591", 
        "arm_group": {
            "arm_group_label": "RO6867461", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, non-randomized, open-label, single-ascending-dose study will investigate\n      the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients\n      with wet age-related macular degeneration. Patients will receive a single intravitreal dose\n      of RO6867461."
        }, 
        "brief_title": "A Study of RO6867461 Administered in Single-Ascending-Dose in Patients With Wet Age-Related Macular Degeneration", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients,  >/= 50 years of age\n\n          -  Patients with age-related macular degeneration (AMG)\n\n          -  Best corrected visual acuity (BCVA) of 20/40 to 20/400 (Snellen equivalent, on ETDRA\n             charts) inclusive\n\n          -  Evidence of leakage due to choroidal neovascularization (CNV)\n\n        Exclusion Criteria:\n\n          -  Choroidal neovascularization (CNV) in either eye due to causes other than age related\n             macular degeneration, such as ocular histoplasmosis, trauma, or pathologic myopia\n\n          -  Known hypersensitivity to ranibizumab, fluorescein, indocyanin green (ICG) or any of\n             the ingredients of the formulation used, or any of the medications used\n\n          -  Any other restriction according to the use of ranibizumab\n\n          -  Active intraocular inflammation (grade trace or above) in the study eye\n\n          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either\n             eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941082", 
            "org_study_id": "BP28936", 
            "secondary_id": "2013-001972-40"
        }, 
        "intervention": {
            "arm_group_label": "RO6867461", 
            "description": "Single ascending dose by intravitreal injection", 
            "intervention_name": "RO6867461", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Colorado Springs", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80909"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belfast", 
                        "country": "United Kingdom", 
                        "zip": "BT12 6BA"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom", 
                        "zip": "BS1 2LX"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "EC1V 2PD"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multiple-Center, Non-Randomized, Open-Label, Single-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration.", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: BP28936 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Ocular safety, assessed by BCVA (EDTRS chart), slitlamp examination, ophthalmoscopy, IOP, fundus photography, SD-OCT, angiography", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941082"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}